--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About AKBA20280121C0.5
Biotechnology Ⅲ
Akebia Therapeutics, Inc., was legally incorporated in Delaware on February 27, 2007. The company is a biopharmaceutical company dedicated to the research and development of novel biological proprietary therapies based on hypoxia-inducible factors and the commercial application of products required by patients with kidney disease. HIF is the primary regulator of new mechanisms of erythropoiesis and potential anemia treatment in the human body. Akebia's lead product candidate, AKB-6548, as a once-daily oral product, has successfully completed a Phase 2 proof-of-concept. Studies have shown that AKB-6548 can safely and effectively increase hemoglobin levels in patients with secondary anemia and chronic kidney disease without the need for dialysis.
